Downloaded 60 times
Uploaded byUzair Ahmed
Pharma marketing
The document discusses marketing management in the pharmaceutical industry. It provides insights into the roles and responsibilities of marketers and brand managers in the industry. It discusses key aspects of marketing management including market research, forecasting, business modeling, communication strategies, training sales teams, monitoring results, and working with third party agencies. It also provides data on the Pakistani pharmaceutical market size and growth of top companies. Global prevalence data and projections for hypertension are presented to illustrate how marketers select markets to serve.
More Related Content
Pharma marketing
- 1. Insights of PharmaIndustry Marketing Management in Pharmaceutical Industry
- 2. WHAT COMES INYOUR MIND WHEN YOU THINK OF MARKETER / BRAND MANAGER
- 3. A man whoThink , Create and Strategies and Make sure Executions of “Each and Everything for Business Growth” Uzair Ahmed – Product Manager – Martin Dow Marker (Pvt) Ltd – 10 Years in Pharmaceutical IndustryUzair Ahmed – Commercial Director Telemedicine Company – Doctor AP. A man who Understand Markets, Anticipate Business opportunities, Able to communicate effectively and efficiently the target audience” Actually…..
- 4. What to Produce, When , Why , How , Communication Strategy , Medium Decisions , Sales Force Products Training , KAM , Forecasting , Budgeting , Resource allocation , Creative Campaigns , Working with Ad and other agencies , Product Launches , Events Management………. Corporate Face (Both Ends) BRAIN OF THE ORGANIZATION
- 6. MARKETING MANAGEMENT ATPHARMACEUTICALS Market Research- What to produce Forecasting and Budgeting Business Model Decision (Pharma Model – In- Direct Selling) Stocks Availabilities after production Communication Development –Content (High Regulations) Training to Field Force/Sales Force Resource Allocations Field Visits to Monitor Sales Team Executions. Product Launch – (Product , Price , Place , Promotions) Monitoring Results Sales Collaterals Development Seminars and Symposiums Creative Campaigns 3rd Party Agencies – Ad. Agencies Territorial/Regional Distribution Working with 3rd Party Agenies- Vendors (Ad,ATL/BTL-Event Management
- 7. Pharmaceutical Data Pharmaceutical BusinessIn Pakistan
- 8. VALUE UNITS MKT SHARE % GR%CAGR% VALUE MKT SHARE % GR% VALUE MKT SHARE % GR% TOTAL INDUSTRY 343,936,391,809 2,604,859,276 100 6.1 11.66 91,762,620,151 100 7.14 30,165,795,026 100 6.48 1 GLAXOSMITHKLINE 25,425,036,140 334,661,875 7.39 2.0 6.15 7,373,825,529 8.04 0.85 2,375,674,154 7.88 1.21 2 ABBOTT LAB PAK LTD 21,632,085,568 188,944,872 6.29 9.8 10.83 5,970,478,650 6.51 10.54 1,943,071,726 6.44 7.41 3 GETZPHARMA 21,426,456,397 100,922,328 6.23 12.4 17.21 5,623,075,140 6.13 10.3 1,860,297,138 6.17 9.31 4 SAMI 18,028,510,183 132,876,531 5.24 9.0 16.24 4,605,769,966 5.02 3.61 1,538,969,378 5.1 6.45 5 MARTIN DOW LIMITED 14,280,245,287 105,285,359 4.15 13.3 11.08 3,712,122,520 4.05 13.8 1,226,649,721 4.07 18.25 10 MERCK 8,692,527,953 76,631,216 2.53 19.1 10.38 2,225,573,576 2.43 15.86 730,506,340 2.42 20.68 17 MARTIN DOW LIMITED 5,385,449,211 27,997,257 1.57 5.4 12.41 1,430,497,425 1.56 10.8 477,859,797 1.58 14.82 151 TEIJIN LTD JAPAN 145,906,852 165,053 0.04 (1.1) 7.44 40,702,896 0.04 12.84 13,530,504 0.04 18.79 214 SEATLE PHARMA 56,361,271 491,833 0.02 22.4 8.28 15,348,623 0.02 10.28 4,753,080 0.02 7.33 6 THE SEARLE COMPANY 12,711,429,268 114,619,830 3.7 10.1 16.72 3,354,569,416 3.66 12.6 1,220,814,983 4.05 2.59 7 SANOFI-AVENTIS PAK 10,651,356,834 73,877,666 3.1 (2.1) 6.15 2,716,267,075 2.96 8.77 888,536,255 2.95 7.15 8 OBS 10,263,419,135 58,945,905 2.98 1.3 6.83 2,607,642,823 2.84 8.61 867,657,910 2.88 9.69 9 GSK CONSUMER 10,237,998,733 101,437,395 2.98 14.8 12.57 2,727,289,265 2.97 9.45 821,028,492 2.72 -0.23 10 HILTON 10,129,279,373 37,490,043 2.95 7.1 14.32 2,663,767,868 2.9 4.95 864,272,544 2.87 5.12 RANK CORPORATES MAT - 12-2017 4THQTR2017 MTH- 12-2017 TOP 10 Pharmaceuticals, MAT Q4 2017
- 9. GSK Abbott GetzSami Martin Dow Searle Sanofi OBS GSK Con Hilton 1,000.0 6,000.0 11,000.0 16,000.0 21,000.0 26,000.0 2.0 9.8 12.4 9.0 13.3 10.1 (2.06) 1.33 14.8 7.1 25,425 21,632 21,426 18,028 14,280 12,711 10,651 10,263 10,237 10,129 Growth % Sales TOP 10 Pharmaceuticals, MAT Q4 2017 Value in Millions
- 10. 25,425 21,632 21,426 18,028 14,280 12,711 10,651 10,263 10,23710,129 GSK Abbott Getz Sami Martin Dow Searle Sanofi OBS GSK Con Hilton - 5,000 10,000 15,000 20,000 25,000 30,000 1 2 3 4 5 6 7 8 9 10 TOP 10 Pharmaceuticals, MAT Q4 2017 Value in Millions
- 11. 14.8 13.3 12.4 10.1 9.8 9.0 7.1 1.3 (2.1) 6.1 2.0 GSK Con Martin Dow Getz SearleAbbott Sami Hilton OBS Sanofi Industry GSK TOP 10 Corporates, % Growth - MAT Q4 2017
- 12. 14.8 13.3 19.1 5.4 … 10.1 9.8 9.0 7.1 1.3 (2.1) 6.1 2.0 GSK Con Martin Dow MDMMDL Getz Searle Abbott Sami Hilton OBS Sanofi Industry GSK TOP 10 Corporates, % Growth - MAT Q4 2017
- 13. HOW SELECT ANYMARKET TO SERVE
- 14. 14 Approximately 4 in10 adults have hypertension, which often goes undiagnosed
- 15.
- 16. 16Source: U.S. CensusBureau, International Data Base, June 2011 Update. World Population: 1950 – 2050 (Billions) Population(billions)
- 17. Global Percentage ofHypertension 2014 17
- 18. 18 Global Percentage ofHypertension 2015
- 19. 19 The Lancet, Volume389, No. 10064; p37-55, January 2017 Global Percentage of Hypertension 2017
- 20. Hypertension – 2025Projections Year 2000 26.4% of the world adult population had hypertension. Total 972 million adults. Highest prevalence in Established Market Economies e.g. Europe. Year 2025 29.2% of the world adult population will have hypertension. Total 1.56 Billion adults, 20% in developed nations & 80% in developing nations. Highest prevalence will be in Developing Continents e.g. Asia, Africa. They will account for 75% of the world’s hypertensive patients. 20 Patricia M Kearney, Megan Whelton, Kristi Reynolds, Paul Muntner, Paul K Whelton, Jiang He, Global burden of hypertension: analysis of worldwide data; The Lancet 2005; Jan 15 -21; 365 (No: 9455): pp 217-23.
- 21.
- 22.
- 23. 23 Source: CDC VitalSigns September 2012, National Health and Nutrition Examination Survey (NHANES) 2003-2010 Hypertension prevalence, awareness, treatment & control in America
- 24. 24 Prince Martin J.,et al; Hypertension prevalence, awareness, treatment and control among older people in Latin America, India and China: a 10/66 cross-sectional population-based survey; Journal of Hypertension: January 2012; Volume 30, Issue 1; p 177-187. Hypertension prevalence, awareness, treatment & control in Asia
- 25. Emelia J. Benjaminet al. Circulation. 2017;135:e146-e603 The 23 leading diagnoses for direct health expenditures, United States, average annual 2012 to 2013 (in billions of dollars).
- 26. Both works, whenthey are OPEN Let’s Discuss Un Resolved Questions of Last Class
- 27. GLOBAL PHARMACUITCAL MARKET INBILLION DOLLARS
- 28. Pakistan Pharma Market 350Billion Rupees. Means $1. 7B -(2019) 2016
- 31.
- 32. How Much Healthcareis Expensive in USA and Europe? Nexium listens for people with complaints about its products and then directs them to its customer service line to find help. Great way to show you’re listening and find new ways to use big investments (like a call center)
- 34. 34 KEEPING IN MIND HeartRate and Life Duration LINK Heart Rate 600 beats / minute Life Expectancy 2 years Heart Rate 6 beats / minute Life Expectancy 177 years